Jefferies Bets on Mirion's Nuclear Future — But Can a $20 Target Stick When Organic Growth Is Barely Moving?

Shares of Mirion Technologies (MIR) surged 6.3% to $16.55 on September 3 after Jefferies initiated coverage with a Buy rating and a $20 price target, implying roughly 28% upside from the prior close. The move was company-specific — major U.S. indexes rose only modestly — and capped a five-session rally of nearly 15% from the August 28 low of $14.40. But the bull case hinges on a nuclear boom that hasn't yet shown up in Mirion's organic results.

• The Nuclear Supercycle Thesis Looks Powerful on Paper. Global nuclear capacity projections now call for 1,446 GWe by 2050 — a 262% increase versus today's roughly 400 GWe.

Mirion booked over $1 billion in orders in 2025, spanning new utility-scale reactors, the installed base, and small modular reactors.

Its backlog swelled to $1.14 billion as of Q2, up 39% year-over-year on a reported basis and 17% excluding acquisitions. Jefferies' $20 target essentially wagers that this pipeline converts into accelerating revenue.

• Organic Growth Tells a More Cautious Story. In Q2, organic revenue grew just 1.2%, and Mirion missed revenue expectations, even as adjusted EPS topped estimates.

Nuclear power revenue was flat organically, as growth in the installed base and SMRs was offset by lower new-build revenue. For a stock that trades at roughly 28× estimated 2026 earnings , investors are paying for a second-half ramp that remains unproven.

• Acquisitions Are Doing the Heavy Lifting — For Now. Q2 revenue hit $266.8 million, up 19.7% year-over-year , but nearly all that growth came from the Paragon and Certrec deals. Full-year 2026 guidance calls for 22–24% revenue growth, including acquisition and FX benefits.

Management expects second-half organic growth to accelerate to 7.5–11.2% — a sharp jump that must materialize to justify Jefferies' optimism.

• Wall Street Is Broadly Bullish, but Price Targets Are Compressing. The consensus target has slipped from $27.40 to $24.80 , and Goldman Sachs recently cut its target to $23 after Q2 results while keeping a Buy. Jefferies' $20 target sits below consensus, suggesting its entry call is less about euphoria and more about flagging Mirion as undervalued relative to peers at current levels.

Bottom line: The nuclear thesis is real, but Mirion must prove it can turn a record backlog into organic revenue growth before the valuation makes full sense.